25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
This month's key California employment law cases involve payment of wages, workplace conditions, pub...
Read More >
Three weeks ago, I wrote about the Bak v Rostek case in Brooklyn Supreme Court addressing the duty t...
Read More >
Welcome to Episode 5 of Compliance Man Chooses the Target with Tim Khasanov-Batirov. My goal is to h...
Read More >
Seyfarth Synopsis: In affirming summary judgment in favor of AutoZone, the Second Circuit rules that...
Read More >
The New Jersey DOL is very aggressive on the issue of independent contractor status, i.e. the issue ...
Read More >
MBlock Investors, LLC v. Bovis Lend Lease, Inc., etc., et al., 44 Fla. L. Weekly d1432 (3d DCA 2019)...
Read More >